drugset / Trial / NCT03572257

Quetiapine Treatment for Pediatric Delirium

NCT03572257 ↗

Phase 2/3 Withdrawn Medical College of Wisconsin
RandomizedParallel-groupTriple-blindTreatment

Summary

This is a prospective, double-blind, randomized controlled trial to begin determining the efficacy of quetiapine as a treatment for pediatric delirium in patients admitted to the pediatric intensive care unit (PICU)

Timeline

Start
2019-04-15
Primary completion
2020-02-27
Completion
2020-03-02

Outcome

Outcome not reported

Stopped (Enrollment): “Closed due to inability to enroll”

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Quetiapine Small molecule 0.5 mg/kg —

Indications